The evidence leans constructive5 supporting, 3 against, 1 worth knowing
Supporting
trading 44% above its 200-day average
matches stretched far above trend, which has beaten the market by +0.87 points over 20 sessions across 27,245 past signals
3 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 15% year on year in the quarter ending 30 June 2026
Against
down 17% over twelve months
1 of the scans it matches has historically underperformed the market
net margin has narrowed from 15.7% to 6.5% across four quarters
Worth knowing
RSI at 80 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 208, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working4
Revenue rose 14.8% year on year, from Rs 71 cr to Rs 81 cr.
+14.8%Rs 71 crRs 81 cr
Trading 43.8% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+43.8%
Turned up over three months while the year is still negative.
+42.6% 3M-17.4% 1Y
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching5
Profit grew slower than revenue, -24.3% against +14.8%.
-24.3%+14.8%
Net profit -24.3% year on year, Rs 7 cr to Rs 5 cr.
-24.3%Rs 7 crRs 5 cr
Net margin fell from 9.8% to 6.5%.
9.8%6.5%
Down 17.4% over the past year.
-17.4%
A warning rule fires on it tonight: stretched far above trend.
Stretched far above trend
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 2 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
7 of 47 matched on 10 Sep
GENESYS matches 7 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
GENESYS trades at 40× trailing earnings, above its median of 29× over this window — 40% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
The Exchange has sought clarification from Genesys International Corporation Ltd on August 27, 2026 with reference to significant movement in price, in order to ensure that investors have ....
Board meeting filings were typically +0.02pt vs the market over the next 5 sessions (n=6,172) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · Order win filings were typically -0.10pt vs the market over the next 5 sessions (n=630)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 15% against the same quarter a year earlier
Going against it
profit dropped 24% year on year
net margin narrowed from 12.2% to 6.5%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
81
8
5
1.26
6.5%
Q4 FY26
31 Mar · consolidated
104
17
13
3.04
12.2%
Q3 FY26
31 Dec · consolidated
76
2
1
0.25
1.4%
Q2 FY26
30 Sep · consolidated
77
15
12
2.89
15.7%
Q1 FY26
30 Jun · consolidated
71
12
7
1.75
9.8%
Q4 FY25
31 Mar · consolidated
94
32
19
4.77
20.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+39.5%
Versus 200-day average+43.8%
Below 52-week high-22.2%
Above 52-week low+123.3%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)79.7
Higher closes in last 54 of 5
Six-month return+62.63%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)7.81%
Volume versus 20-day3.1x
Median daily turnoverRs 20.9 cr
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
10 Sep
2
Rising on most days lately, Short averages stacked in order
9 Sep
2
Rising on most days lately, Golden cross — 50 crossed above 200
8 Sep
3
Rising on most days lately, Closed at the very top of its range, Short averages stacked in order
27 Aug
1
Falling on heavy volume
26 Aug
2
Trading far more than usual, MACD just turned positive